NEW YORK (GenomeWeb News) – Danaher said today that its revenues in the fourth quarter rose 6 percent year over year with its Life Sciences & Diagnostics segment leading the way.

For the three months ended Dec. 31, 2013, the company posted revenues of $5.27 billion, up from $4.98 billion in Q4 2012, and beating the consensus Wall Street estimate of $5.20 billion.

Danaher's profit for the quarter was up to $789.3 million, or $1.11 per share, from $630.4 million, or $0.89 per share, in Q4 2012, besting analyst estimates of $0.95 per share.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

Science speaks with the University of Michigan's Jedidiah Carlson, who has tracked population genetic discussions at white nationalist sites.

Gene therapies could qualify for a faster US Food and Drug Administration approval process, according to Stat News.

NPR reports that the US House of Representatives has passed a bill to enable terminally ill patients access to experimental drugs.

In Genome Research this week: inversion variants mapped in human, non-human primate genomes; transcriptome profiling of maize, sorghum; and more.

Jun
19
Sponsored by
Advanced Cell Diagnostics

This webinar will provide evidence for the use of RNA in situ hybridization (RNA ISH) as a replacement for immunohistochemistry (IHC) in cancer research and diagnostic applications.